Swedish Orphan Biovitrum (SOBI) Stock Overview
A biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SOBI Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 383.00 |
| 52 Week High | SEK 432.80 |
| 52 Week Low | SEK 241.80 |
| Beta | 0.23 |
| 1 Month Change | -5.53% |
| 3 Month Change | 16.27% |
| 1 Year Change | 30.63% |
| 3 Year Change | 57.68% |
| 5 Year Change | 168.21% |
| Change since IPO | 243.50% |
Recent News & Updates
Recent updates
Pipeline And Margin Risks Will Challenge Rare Disease Expansion Narrative
Catalysts About Swedish Orphan Biovitrum Swedish Orphan Biovitrum focuses on rare disease medicines across hematology, immunology and specialty care. What are the underlying business or industry changes driving this perspective?
Launch Wave In Rare Disease Treatments Will Redefine Long Term Potential
Catalysts About Swedish Orphan Biovitrum Swedish Orphan Biovitrum focuses on rare diseases in hematology, immunology and specialty care, with a growing portfolio of high-value medicines. What are the underlying business or industry changes driving this perspective?Swedish Orphan Biovitrum AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 08
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Jan 05Why Investors Shouldn't Be Surprised By Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Low P/S
Dec 01Swedish Orphan Biovitrum's (STO:SOBI) Soft Earnings Are Actually Better Than They Appear
Oct 28Here's Why Swedish Orphan Biovitrum (STO:SOBI) Has Caught The Eye Of Investors
Oct 19We Think Swedish Orphan Biovitrum (STO:SOBI) Can Stay On Top Of Its Debt
Aug 04Results: Swedish Orphan Biovitrum AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 19Are Investors Undervaluing Swedish Orphan Biovitrum AB (publ) (STO:SOBI) By 49%?
Jul 03Swedish Orphan Biovitrum AB (publ) Just Recorded A 30% EPS Beat: Here's What Analysts Are Forecasting Next
May 02Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Price In Tune With Earnings
Apr 18
Innovative Product Launches And Global Expansion Drive Bright Future In Sobi's Portfolio
Expansion of hematology and immunology divisions, with new product launches, drives strong revenue growth and market positioning.Shareholder Returns
| SOBI | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 5.7% | 1.5% | -2.5% |
| 1Y | 30.6% | 12.3% | 2.7% |
Return vs Industry: SOBI exceeded the Swedish Biotechs industry which returned 12.3% over the past year.
Return vs Market: SOBI exceeded the Swedish Market which returned 2.7% over the past year.
Price Volatility
| SOBI volatility | |
|---|---|
| SOBI Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 12.5% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: SOBI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SOBI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,888 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| SOBI fundamental statistics | |
|---|---|
| Market cap | SEK 131.56b |
| Earnings (TTM) | SEK 478.00m |
| Revenue (TTM) | SEK 28.24b |
Is SOBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOBI income statement (TTM) | |
|---|---|
| Revenue | SEK 28.24b |
| Cost of Revenue | SEK 5.97b |
| Gross Profit | SEK 22.27b |
| Other Expenses | SEK 21.79b |
| Earnings | SEK 478.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 31, 2026
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 78.87% |
| Net Profit Margin | 1.69% |
| Debt/Equity Ratio | 29.5% |
How did SOBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/26 23:43 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 28 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Rosie Turner | Barclays |
| Brian Balchin | Barclays |